Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

NCT06988605 is registered in ClinicalTrials.gov with Galderma R&D as lead sponsor.

NCT NCT06988605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06988605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Lead sponsor
Galderma R&D
Phase
Observational
Overall status
Recruiting
Start date
July 14, 2025
Completion date
November 30, 2027
Enrollment
1,000 (estimated)
Sites
108

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis